Results 51 to 60 of about 7,977 (217)

Exploring retinal vessel density alterations in prolactinoma patients: Insights from OCTA imaging

Indian Journal of Ophthalmology
Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA). Design: A retrospective study.
Serife Ciloglu Hayat, Yusuf Cem Yilmaz, Merve Kelebek, Esra Hatipoglu   +3 more
doaj   +1 more source

Management of prolactinoma during pregnancy and postpartum

Journal of Integrated Health Sciences, 2015
Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani, Rishma Lakhani, M Desai, M Tripathi   +3 more
doaj   +1 more source

Aggressive giant prolactinoma: a case report

Journal of Medical Case Reports, 2022
Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan, Florence Hui Sieng Tan   +1 more
doaj   +1 more source

Visual, vestibular, and ocular motor changes during nitroglycerin‐triggered vestibular migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 9, Page 1991-2005, October 2026.
Plain Language Summary Vestibular migraine (VM) is a common cause of intermittent dizziness, but there have been no studies with provoked (induced) VM used to characterize how the vestibular and ocular (vision) systems interact. We injected 20 patients with VM with nitroglycerin to provoke an attack and used a specialized camera to record their eye ...
Maria Dolores Villar‐Martinez, Francesca Puledda, Caroline Domingos‐Belo, Adolfo M. Bronstein, Peter J. Goadsby   +4 more
wiley   +1 more source

Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma

, 2022
SIMPLE SUMMARY: This review updates recent advances in the pathogenesis, diagnosis, and therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine tumors, frequently occur in females aged 20 to 50 and cause hypogonadism and
Nishiyama, Mitsuru, Iwasaki, Yasumasa, Mitsuru Nishiyama, Yasumasa Iwasaki, Fukuhara, Noriaki, Noriaki Fukuhara   +5 more
core   +1 more source

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

Journal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe   +6 more
doaj   +1 more source

The PRolaCT studies — a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma

Trials, 2021
Background First-line treatment for prolactinomas is a medical treatment with dopamine agonists (DAs), which effectively control hyperprolactinaemia in most patients, although post-withdrawal remission rates are approximately 34%.
Ingrid M. Zandbergen, Amir H. Zamanipoor Najafabadi, Iris C. M. Pelsma, M. Elske van den Akker-van Marle, Peter H. L. T. Bisschop, H. D. Jeroen Boogaarts, Arianne C. van Bon, Bakhtyar Burhani, Saskia le Cessie, Olaf M. Dekkers, Madeleine L. Drent, Richard A. Feelders, Johan P. de Graaf, J. Hoogmoed, Kitty K. Kapiteijn, Melanie M. van der Klauw, Willy-Anne C. M. Nieuwlaat, Alberto M. Pereira, Aline M. E. Stades, Annenienke C. van de Ven, Iris M. M. J. Wakelkamp, Wouter R. van Furth, Nienke R. Biermasz, on behalf of the Dutch Prolactinoma Study Group   +23 more
doaj   +1 more source

Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Prolactinomas in the transition age present unique challenges; treatment strategies and long‐term outcomes in this population remain incompletely characterised. This is a multicentre, retrospective study of 110 consecutive patients (33 males) with prolactinomas, aged 15–25 years, across five Italian referral centres (2010–2025).
Dario De Alcubierre, Claudia Giavoli, Tiziana Feola, Lorenzo Cerroni, Ludovica Vincenzi, Eriselda Profka, Aurora Pedroli, Giulia Puliani, Rosa Pirchio, Marta Tenuta, Renata S. Auriemma, Maria Luisa Appetecchia, Rosario Pivonello, Giovanna Mantovani, Andrea M. Isidori, Marie‐Lise Jaffrain‐Rea, Ashley Grossman, Emilia Sbardella   +17 more
wiley   +1 more source

Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients.

, 2013
Prolactinoma is the most frequent pituitary tumour among women of child-bearing age. Only a few studies have addressed the outcome of prolactinoma after pregnancy.JOURNAL ARTICLESCOPUS: ar.jFLWINinfo:eu-repo/semantics ...
Devuyst, France, Corvilain, Bernard, Maiter, Dominique, Alexopoulou, Orsalia, Domingue, Marie-Eve   +4 more
core   +1 more source

The Efficacy of Pharmacotherapy Intervention on Anthropometric Outcomes in Survivors of Childhood Brain Tumors: An Updated Systematic Review and Meta‐Analysis

Obesity Reviews, Volume 27, Issue 10, October 2026.
ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart, Lawrence Mbuagbaw, Joseph Beyene, Marwa Akola, Sarah Burrow, M. Constantine Samaan, Lehana Thabane, Adam Fleming, Donna L. Johnston, Shahrad R. Rassekh, Laura Banfield, Russell J. de Souza   +11 more
wiley   +1 more source